What caused the ABT.SW stock drop in pre-market on 24 Feb 2026?

The pre-market fall to **CHF86.50** (-13.50%) was driven by low SIX liquidity and sector rotation; no single new release explains the move, and traders are positioning ahead of Abbott’s earnings on 2026-04-15.

What is Meyka AI’s price forecast for ABT.SW stock?

Meyka AI's model projects a yearly target of **CHF100.56** (implied upside **16.26%**) and a quarterly target of **CHF109.55** (implied upside **26.64%**). These are model projections and not guarantees.

Is ABT.SW stock a buy after this drop?

Meyka AI grades ABT.SW **74.40/100 (B+, BUY)** based on growth, metrics and forecasts, but third-party companyRating shows a **C / Sell**. Evaluate your risk tolerance and upcoming earnings before acting.

What technical levels should traders watch for ABT.SW stock?

Key levels: near-term support **CHF85.00** (year low), short-term resistance **CHF95.35** (50-day MA), and psychological range **CHF100.00–CHF110.00** depending on post-earnings momentum.

CH Stocks

ABT.SW Abbott Laboratories (SIX) down 13.50% pre-market: CHF86.50 support to watch

ByDanny Kontos February 24, 2026

ABT.SW stock opened pre-market on 24 Feb 2026 at CHF86.50, down 13.50% from the previous close of CHF100.00 as traders reacted to weak session flow and sector rotation. This move places Abbott Laboratories (ABT.SW) on the Swiss SIX top losers list and tests the near-term support near the year low of CHF85.00. We look at valuation, technical signals, Meyka AI grading and model forecasts to explain the drop and what could re-anchor the share price in Swiss trading.